2023
DOI: 10.1016/j.bja.2023.02.026
|View full text |Cite
|
Sign up to set email alerts
|

Pholcodine exposure increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: the ALPHO case-control study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(3 citation statements)
references
References 25 publications
(21 reference statements)
0
2
0
Order By: Relevance
“…Multiple logistic regression was used to adjust for potential confounders to obtain the adjusted OR and 95% CI. 13 The ROC curve was plotted and the area under the curve was calculated. All statistical analyses were performed using R software (R version 4.1.2) and SPSS (Version 20.0; IBM Statistics, Armonk, NY).…”
Section: Methodsmentioning
confidence: 99%
“…Multiple logistic regression was used to adjust for potential confounders to obtain the adjusted OR and 95% CI. 13 The ROC curve was plotted and the area under the curve was calculated. All statistical analyses were performed using R software (R version 4.1.2) and SPSS (Version 20.0; IBM Statistics, Armonk, NY).…”
Section: Methodsmentioning
confidence: 99%
“…The screening of patients for pholcodine use prior to the planned administration of an NMBA is not recommended, and patients who report pholcodine use should still receive an NMBA if this is clinically indicated. The impact of pholcodine withdrawal on incidence of NMBA allergy will be evaluated over the coming years [62][63][64].…”
Section: Avoiding Future Reactionsmentioning
confidence: 99%
“…Later in 2022, the European Medicines Agency (EMA) [ 7 ], the British government [ 8 ], and the World Health Organization (WHO) [ 9 ] issued reports highlighting the potential risk of perioperative anaphylactic shock associated with PHL use (up to 12 months prior to surgery) in combination with neuromuscular blocking agents [ 10 12 ]. This newly identified risk called the "ALPHO case study" [ 13 ], emphasizes the potential for serious adverse reactions beyond what was previously known. As a result, several markets have taken further steps to restrict PHL, either fully banning its OTC sale or requiring a prescription [ 7 – 12 ].…”
Section: Introductionmentioning
confidence: 99%